Whats new at endoceutics? QUEBEC CITY, Nov. 6, 2019 /CNW Telbec/ - Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy. INTRAROSA is offered as a vaginal ovule containing 6.5 mg of prasterone.Who is endoceutics and lupin pharma? Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize INTRAROSA ® in Canada.Where is endoceutics building in canada? Oct 2017: Endoceutics is starting the construction of its industrial complex in Ancienne-Lorette, Quebec, Canada. The Mayor of Ancienne-Lorette has given Dr. Fernand Labrie the building permit required for phase 1 of the 45,785 m 2 project and some $ 80 million.What happened to endoceutics intrarosa? Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a pestiture process announced in January 2020 by AMAG Pharmaceuticals.
Endoceutics is a private pharmaceutical company operating in the fields of women’s health and hormone-sensitive cancer prevention and treatment. Endoceutics is actively committed to advancing basic sciences, clinical research and development, world-class manufacturing, and product commercialization worldwide. EndoCeutics, Inc., CMOCRO, PharmaCircle, ...